Fresenius Group Overview

05.09.2016

DGAP Ad-hoc - Fresenius SE & Co. KGaA: Fresenius Helios acquires largest private Spanish hospital group Quirónsalud

  • Contact

    Markus Georgi

    Senior Vice President Investor Relations
    T: +49 (0) 6172 608-2485
    markus.georgi@fresenius.com

Fresenius SE & Co. KGaA: Fresenius Helios acquires largest private Spanish hospital group Quirónsalud


Fresenius SE & Co. KGaA / Key word(s): Mergers & Acquisitions

05.09.2016 21:34

Disclosure of an inside information according to Article 17 MAR,
transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Fresenius Helios acquires largest private Spanish hospital group
Quirónsalud

Fresenius Helios acquires IDC Salud Holding S.L.U. ("Quirónsalud"), Spain's
largest private hospital operator, for a purchase price of EUR5.76 billion
(on a cash and debt-free basis). Quirónsalud's network is comprised of 43
hospitals, 39 outpatient centers and around 300 Occupational Risk
Prevention ("ORP") centers located in all economically important areas in
Spain. The company has about 35,000 employees and offers the full spectrum
of inpatient and outpatient care. Quirónsalud was created by the merger of
IDC Salud ("IDC") and Grupo Hospitalario Quirón ("GHQ") in 2014.

Quirónsalud has posted organic sales growth of more than 5% p.a. in recent
years. Growth is driven by an above-market increase of patient admissions
due to excellent quality of care combined with consistently short waiting
times.

For 2016, Quirónsalud expects sales of approximately EUR2.5 billion and
EBITDA of EUR460 to EUR480 million. In 2017, EBITDA is expected to be in
the range of EUR520 to EUR550 million. The purchase price corresponds to
approximately 10.8x at the mid-point of the 2017 EBITDA range.

Key drivers of the anticipated EBITDA growth are already implemented
synergy projects related to the 2014 merger of IDC and GHQ, recent
acquisitions, well-advanced efficiency projects as well as operating
leverage. Neither greenfield projects, further acquisitions nor synergies
with HELIOS are included in the 2017 projections. In the medium-term, the
merger of HELIOS and Quirónsalud is expected to lead to incremental pre-tax
synergies of approximately EUR50 million p.a. without meaningful
implementation expenses.

Fresenius Helios acquires 100% of the share capital in Quirónsalud. Sellers
are the private equity group CVC Capital Partners, the founder and CEO of
Quirónsalud Víctor Madera, as well as other members of Quirónsalud's
management board.

Fresenius will issue 6,108,176 shares valued at EUR400 million to Víctor
Madera who has agreed to a two year lock-up period. The balance of the
purchase price will be debt-financed.

Group net debt/EBITDA will temporarily increase to approximately 3.1.
Already in mid-2017, the leverage ratio is expected to return to the 2.5 to
3.0 target range.

The transaction is subject to regulatory approval by the relevant antitrust
authorities and is expected to close in Q4/2016 or Q1/2017.

The transaction is expected to be accretive to Group net income
attributable to shareholders of Fresenius SE & Co. KGaA and earnings per
share attributable to shareholders of Fresenius SE & Co. KGaA already in
2017.

Given the expected meaningful accretion to Group sales and earnings,
Fresenius will publish new mid-term targets as part of its full-year 2016
reporting.

Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
Board of Management

Bad Homburg v.d.H., 5 September 2016

For additional information on the performance indicators used please refer
to pages 25, 40, 56f., 100f. and 194 of the Annual Report 2015 of Fresenius
SE & Co. KGaA.

Contact:
Markus Georgi
Senior Vice President Investor Relations
T: +49 (0) 6172 608-2485
markus.georgi@fresenius.com

End of note


05.09.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE0005785604
WKN: 578560
Indices: DAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard),
Munich; Regulated Unofficial Market in Berlin, Hamburg,
Hanover, Stuttgart, Tradegate Exchange

End of Announcement DGAP News-Service

---------------------------------------------------------------------------